PCSK9: A new participant in lipophagy in regulating atherosclerosis?

被引：10

作者：

Xiao, Jun ^{[1
]}

Deng, Yi-Min ^{[1
]}

Liu, Xiang-Rui ^{[1
]}

Cao, Jian-Ping ^{[2
]}

Zhou, Min ^{[1
]}

Tang, Ya-Ling ^{[1
]}

Xiong, Wen-Hao ^{[1
]}

Jiang, Zhi-Sheng ^{[1
]}

Tang, Zhi-Han ^{[1
]}

Liu, Lu-Shan ^{[1
]}

机构：

[1] Univ South China, Hunan Int Sci & Technol Cooperat Base Arterioscle, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China

[2] Hunan Environm Biol Vocat & Tech Coll, Hengyang 421001, Hunan, Peoples R China

来源：

CLINICA CHIMICA ACTA | 2019年 / 495卷

基金：

中国国家自然科学基金;

关键词：

Proprotein convertase subtilisin kexin 9; Lipophagy; Lipid metabolism; Low density lipoprotein receptor; Atherosclerosis; SUBTILISIN/KEXIN TYPE 9; LIPID DROPLETS; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; APOLIPOPROTEIN-B; RAB7; EFFECTOR; LIVER-DISEASE; AUTOPHAGY; PROTEIN; DEGRADATION;

D O I：

10.1016/j.cca.2019.05.005

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis.

引用

页码：358 / 364

页数：7

共 50 条

[31] Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
Punch, Emily
Klein, Justus
Diaba-Nuhoho, Patrick
Morawietz, Henning
Garelnabi, Mahdi
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (03):
[32] BINDING OF PCSK9 TO CIRCULATING LDL: EFFECT OF PCSK9 MONOCLONAL ANTIBODIES ON THE LDL-BOUND PCSK9?
De Stefano, D.
Baragetti, A.
Baragetti, A.
Macri, N.
Tavori, H.
Fazio, S.
Catapano, A. L.
ATHEROSCLEROSIS, 2018, 275 : E101 - E101
[33] New Pharmacological Approaches to Target PCSK9
Catapano, Alberico L.
Pirillo, Angela
Norata, Giuseppe D.
CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (07)
[34] PCSK9: a new marker of metabolic syndromes
Le Bras, M.
Letessier, E.
Jacobi, D.
Huten, N.
Mosnier, J. F.
Benoit, I.
Krempf, M.
Arnaud, L.
Costet, P.
Cariou, B.
DIABETES & METABOLISM, 2012, 38 : A19 - A19
[35] Commentary PCSK9 variants: A new database
Leigha, Sarah E. A.
Leren, Trond P.
Humphries, Steve E.
ATHEROSCLEROSIS, 2009, 203 (01) : 32 - 33
[36] PCSK9 inhibitors: A new improvement for health
Perello Camacho, Eva
CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2019, 31 (05): : 241 - 243
[37] PCSK9 as new target in hyperlipidemia treatment
Stawowy, P.
Kelle, S.
Fleck, E.
HERZ, 2014, 39 (04) : 466 - 469
[38] New Pharmacological Approaches to Target PCSK9
Alberico L. Catapano
Angela Pirillo
Giuseppe D. Norata
Current Atherosclerosis Reports, 2020, 22
[39] PCSK9 inhibitors
Farnier, Michel
CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2015, 19 (03): : 66 - 70
[40] PCSK9 inhibitors
Farnier, Michel
CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (03) : 251 - 258

← 1 2 3 4 5 →